| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S11892-002-0072-8 |
| P698 | PubMed publication ID | 12643133 |
| P2093 | author name string | David C Henderson | |
| P2860 | cites work | Weight gain associated with psychotropic drugs | Q69369784 |
| Diabetic ketoacidosis from clozapine and lithium cotreatment | Q71043901 | ||
| Serum triglyceride levels in patients treated with clozapine | Q71686025 | ||
| Severe hyperglycemia associated with high doses of clozapine | Q72144500 | ||
| Diabetic ketoacidosis associated with clozapine treatment | Q72205009 | ||
| New-onset diabetes mellitus associated with quetiapine | Q73136625 | ||
| Diabetic ketoacidosis associated with risperidone treatment? | Q74037787 | ||
| DRUG-PRODUCED OBESITY. EXPERIENCES WITH CHLORPROMAZINE, PERPHENAZINE AND CLOPENTHIXOL | Q76956886 | ||
| A fatal drug interaction between clozapine and fluoxetine | Q77211280 | ||
| Clozapine-induced diabetic ketoacidosis | Q77305210 | ||
| Schizophrenia and diabetes mellitus | Q77349983 | ||
| Novel antipsychotics and new onset diabetes | Q77496512 | ||
| Risperidone treatment for a patient suffering from schizophrenia and IDDM | Q77588741 | ||
| Excess mortality of mental disorder | Q77670488 | ||
| Diabetic ketoacidosis associated with clozapine treatment | Q77765037 | ||
| Diabetic ketoacidosis with olanzapine treatment | Q77892219 | ||
| Hyperglycemia associated with olanzapine | Q77915802 | ||
| New-onset diabetes mellitus and diabetic ketoacidosis associated with olanzapine treatment | Q78235395 | ||
| Olanzapine-induced ketoacidosis with diabetes mellitus | Q78254989 | ||
| Olanzapine-induced elevation of plasma triglyceride levels | Q78254993 | ||
| New-onset diabetes mellitus associated with the initiation of quetiapine treatment | Q78257945 | ||
| Antipsychotic-induced weight gain: a comprehensive research synthesis | Q28146256 | ||
| Clozapine-associated reduction in arrest rates of psychotic patients with criminal histories | Q31825600 | ||
| The effects of clozapine on aggression and substance abuse in schizophrenic patients | Q33662417 | ||
| Metabolic studies in unaffected co-twins of non-insulin-dependent diabetics. | Q34779949 | ||
| Weight gain among schizophrenic patients treated with clozapine | Q35254182 | ||
| Kelly West Lecture 1991. Challenges in diabetes epidemiology--from West to the rest | Q35914322 | ||
| The effect of antipsychotic drugs on body weight: a retrospective review | Q39282355 | ||
| Weight gain associated with neuroleptic medication: a review | Q40371451 | ||
| Medical hazards of obesity | Q40841355 | ||
| Insulin resistance versus insulin secretion in the hypertension of obesity | Q41114753 | ||
| Toward an integrated phenotype in pre-NIDDM. | Q41190692 | ||
| Clozapine reduces violence and persistent aggression in schizophrenia | Q41738224 | ||
| Efficacy of risperidone treatment for psychoses associated with schizophrenia, schizoaffective disorder, bipolar disorder, or senile dementia in 11 geriatric patients: a case series | Q42276723 | ||
| Diabetic ketoacidosis and clozapine | Q43199860 | ||
| Diabetes mellitus in schizophrenic patients | Q43600057 | ||
| Clozapine-induced weight gain: prevalence and clinical relevance | Q45169845 | ||
| Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study | Q47238068 | ||
| Olanzapine increases weight and serum triglyceride levels. | Q47252169 | ||
| Weight gain among patients on clozapine | Q47265163 | ||
| Differential effect of clozapine on weight: a controlled study | Q47331289 | ||
| Clozapine and weight gain. | Q47370064 | ||
| Weight gain associated with clozapine | Q47448570 | ||
| Mortality in current and former users of clozapine. | Q50928138 | ||
| Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses. | Q51552711 | ||
| Different influences of classical antipsychotics and clozapine on glucose-insulin homeostasis in patients with schizophrenia or related psychoses. | Q51559601 | ||
| Prevalence of diabetes and impaired glucose tolerance in patients treated with clozapine compared with patients treated with conventional depot neuroleptic medications. | Q51992671 | ||
| Prevalence and correlates of diabetes in national schizophrenia samples. | Q53506906 | ||
| Ketoacidosis as a side-effect of clozapine: a case report | Q59221805 | ||
| P433 | issue | 2 | |
| P304 | page(s) | 135-140 | |
| P577 | publication date | 2002-04-01 | |
| P1433 | published in | Current diabetes report | Q26841965 |
| P1476 | title | Diabetes mellitus and other metabolic disturbances induced by atypical antipsychotic agents | |
| P478 | volume | 2 |
| Q44635621 | A Pilot Study of Risperidone, Olanzapine, and Haloperidol in Psychotic Youth: A Double-Blind, Randomized, 8-Week Trial |
| Q45013063 | Adverse effects of atypical antipsychotic agents and their effects on quality of life |
| Q39789971 | Age-specific prevalence of metabolic syndrome in Italian patients with bipolar disorder. |
| Q45212721 | Characterizing coronary heart disease risk in chronic schizophrenia: high prevalence of the metabolic syndrome |
| Q33890082 | Functional deficits in the extrastriate body area during observation of sports-related actions in schizophrenia |
| Q91630686 | Intersectional decomposition analysis with differential exposure, effects, and construct |
| Q47254506 | Pilot study of a cognitive behavioral group intervention to prevent further weight gain in Hispanic individuals with schizophrenia |
| Q35791125 | Randomized pilot study of cabergoline, a dopamine receptor agonist: effects on body weight and glucose tolerance in obese adults |
Search more.